FDA Approved: ONTRUZANT — Supplemental Application (Organon LLC)

View source ↗

Summary

FDA approves a supplemental application for ONTRUZANT (trastuzumab) filed by Organon LLC, resulting in changes to the product labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• ONTRUZANT (TRASTUZUMAB)

Snippet

SUPPL AP for ONTRUZANT (TRASTUZUMAB)